Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cardiff Oncology, Inc. before investing.

In this article, we go over a few key elements for understanding Cardiff Oncology, Inc.’s stock price such as:

• Cardiff Oncology, Inc.’s current stock price and volume
• Why Cardiff Oncology, Inc.’s stock price changed recently
• Upgrades and downgrades for CRDF from analysts
• CRDF’s stock price momentum as measured by its relative strength

About Cardiff Oncology, Inc. (CRDF)

Before we jump into Cardiff Oncology, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Want to learn more about Cardiff Oncology, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cardiff Oncology, Inc..

Cardiff Oncology, Inc.’s Stock Price as of Market Close

As of September 04, 2026, 4:00 PM, CST, Cardiff Oncology, Inc.’s stock price was $1.090.

Cardiff Oncology, Inc. is up 0.93% from its previous closing price of $1.080.

During the last market session, Cardiff Oncology, Inc.’s stock traded between $1.065 and $1.100. Currently, there are approximately 68.40 million shares outstanding for Cardiff Oncology, Inc..

Cardiff Oncology, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cardiff Oncology, Inc. Stock Price History

Cardiff Oncology, Inc.’s (CRDF) price is currently up 9.7% so far this month.

During the month of September, Cardiff Oncology, Inc.’s stock price has reached a high of $1.100 and a low of $1.000.

Over the last year, Cardiff Oncology, Inc. has hit prices as high as $3.310 and as low as $0.757. Year to date, Cardiff Oncology, Inc.’s stock is down 61.21%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cardiff Oncology, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 04, 2026, there was 1 analyst who downgraded Cardiff Oncology, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cardiff Oncology, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cardiff Oncology, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Cardiff Oncology, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cardiff Oncology, Inc. (CRDF) by visiting AAII Stock Evaluator.

Relative Price Strength of Cardiff Oncology, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 04, 2026, Cardiff Oncology, Inc. has a weighted four-quarter relative price strength of -20.80%, which translates to a Momentum Score of 11 and is considered to be Very Weak.

Want to learn more about how Cardiff Oncology, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cardiff Oncology, Inc. Stock Price: Bottom Line

As of September 4, 2026, Cardiff Oncology, Inc.’s stock price is $1.090, which is up 0.93% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cardiff Oncology, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.